Phoenix Holdings Ltd. Lineage Cell Therapeutics, Inc. Transaction History

Phoenix Holdings Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$1.02 - $1.5 $1,151 - $1,693	1,129 Added 2.37%	48,716 $56,000
Q3 2022 Nov 10, 2022	SELL	$1.13 - $1.77 $147,181 - $230,540	-130,249 Reduced 73.24%	47,587 $55,000
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $74,245 - $106,728	66,291 Added 59.43%	177,836 $282,000
Q1 2022 May 10, 2022	SELL	$1.21 - $2.48 $14,908 - $30,556	-12,321 Reduced 9.95%	111,545 $172,000
Q4 2021 Feb 07, 2022	BUY	$1.84 - $2.68 $227,913 - $331,960	123,866 New	123,866 $306,000

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $84.9M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Phoenix Holdings Ltd., based on Form 13F filings with the SEC.

Stay updated on Phoenix Holdings Ltd. with notifications on news.